Pfizer has released the results of a sub-analysis that is part of the phase 3 Paloma-2 clinical trial involving Ibrance combined with letrozole.
The sub-analysis studied Asian patients participating in the trial and showed that the combination significantly extended progression-free survival (PFS).
The Ibrance-letrozole combination was evaluated for the first-line treatment of women who are postmenopausal and estrogen receptor-positive.
“It is exciting to see that the significant efficacy shown in the Paloma-2 trial extends to Asian patients, further supporting the potential for Ibrance to be a standard of care treatment in Asia Pacific, a region where more than 600,000 women are affected by breast cancer each year,” Pfizer Oncology Regional Medical Lead Dr. Mahmood Alam said.
Data from the sub-analysis from the phase 3 Paloma-2 trial was presented at the second ESMO Asia Congress in Singapore.
“Across the Asia Pacific region, breast cancer has grown into a major health concern, with significant increases in breast cancer incidence in recent years in several Asian countries,” Dr. Seock-Ah Im, who works at the Seoul National University Hospital, said. “Patients with metastatic breast cancer, in particular those in Asia, eagerly await new and innovative treatment options.”
